Buscar
Vertex Pharmaceuticals Inc
VRTXAñadir a la lista de seguimiento
546.120USD
-11.840-2.12%
Cierre 09-04 16:00（ET）
138.38BCap. mercado
32.12P/E TTM
Más Datos de Vertex Pharmaceuticals Inc Compañía
Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).
Perfil de Vertex Pharmaceuticals Inc
Símbolo de cotizaciónVRTX
Nombre de la empresaVertex Pharmaceuticals Inc
Fecha de salida a bolsaJul 24, 1991
Director ejecutivoKewalramani (Reshma)
Número de empleados6100
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 24
Dirección50 Northern Avenue
CiudadBOSTON
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02210
Teléfono16173416393
Sitio Webhttps://www.vrtx.com/
Símbolo de cotizaciónVRTX
Fecha de salida a bolsaJul 24, 1991
Director ejecutivoKewalramani (Reshma)
Ejecutivos de Vertex Pharmaceuticals Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Reshma Kewalramani, M.D.
Dr. Reshma Kewalramani, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
47.80K
+28.61%
Dr. Reshma Kewalramani, M.D.
Dr. Reshma Kewalramani, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
47.80K
+28.61%
Dr. Reshma Kewalramani, M.D.
Dr. Reshma Kewalramani, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
47.80K
+28.61%
Mr. Bruce I. Sachs
Mr. Bruce I. Sachs
Lead Independent Director
Lead Independent Director
39.00K
-15.38%
Mr. Bruce I. Sachs
Mr. Bruce I. Sachs
Lead Independent Director
Lead Independent Director
39.00K
-15.38%
Mr. Bruce I. Sachs
Mr. Bruce I. Sachs
Lead Independent Director
Lead Independent Director
39.00K
-15.38%
Dr. Ourania (Nia) Tatsis, Ph.D.
Dr. Ourania (Nia) Tatsis, Ph.D.
Executive Vice President, Chief Regulatory and Quality Officer
Executive Vice President, Chief Regulatory and Quality Officer
36.25K
+18.62%
Dr. Ourania (Nia) Tatsis, Ph.D.
Dr. Ourania (Nia) Tatsis, Ph.D.
Executive Vice President, Chief Regulatory and Quality Officer
Executive Vice President, Chief Regulatory and Quality Officer
36.25K
+18.62%
Dr. Ourania (Nia) Tatsis, Ph.D.
Dr. Ourania (Nia) Tatsis, Ph.D.
Executive Vice President, Chief Regulatory and Quality Officer
Executive Vice President, Chief Regulatory and Quality Officer
36.25K
+18.62%
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
35.24K
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Reshma Kewalramani, M.D.
Dr. Reshma Kewalramani, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
47.80K
+28.61%
Dr. Reshma Kewalramani, M.D.
Dr. Reshma Kewalramani, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
47.80K
+28.61%
Dr. Reshma Kewalramani, M.D.
Dr. Reshma Kewalramani, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
47.80K
+28.61%
Mr. Bruce I. Sachs
Mr. Bruce I. Sachs
Lead Independent Director
Lead Independent Director
39.00K
-15.38%
Mr. Bruce I. Sachs
Mr. Bruce I. Sachs
Lead Independent Director
Lead Independent Director
39.00K
-15.38%
Mr. Bruce I. Sachs
Mr. Bruce I. Sachs
Lead Independent Director
Lead Independent Director
39.00K
-15.38%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Vertex Pharmaceuticals Inc?
Los cinco principales accionistas de Vertex Pharmaceuticals Inc son: Dr. Reshma Kewalramani, M.D.
¿Cuántas instituciones poseen acciones de Vertex Pharmaceuticals Inc (VRTX)?
A fecha de 2026Q1, 3075 instituciones poseen acciones de Vertex Pharmaceuticals Inc, con un valor de mercado combinado de aproximadamente 247.47M, lo que representa el 97.50% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -4593876.00.
¿Cuál es la mayor fuente de ganancias de Vertex Pharmaceuticals Inc?
El 2026Q1, el segmento empresarial TRIKAFTA generó la ganancia más alta para Vertex Pharmaceuticals Inc, ascendiendo a 2.50B y representando el 74.90% de la ganancia total.